Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2024 Nov 11;15:1519505. doi: 10.3389/fphar.2024.1519505

Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China

Lu Li 1, Shilei Yang 1, Fengqi Fang 2, Li Tian 1, Ying He 1, Jia Li 2,*, Yanwei Chen 1,*, Deshi Dong 1,*
PMCID: PMC11589814  PMID: 39600366

In the published article, there was an error. T-DXd was indicated for comparison with PC strategies instead of T-DM1.

A correction has been made to the Abstract, Findings. This sentence previously stated:

“The PC strategies are considered more cost-effective than T-DXd when the WTP threshold is set at $36,058.06 per QALY.”

The corrected sentence appears below:

“The PC strategies are considered more cost-effective than T-DM1 when the WTP threshold is set at $36,058.06 per QALY.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES